Publications
26
Citations
1,379
Est. group size
~4
Recurring co-author estimate
Active years
19
Publishing since 2007
Victor S. Van Laar's research focuses on Parkinson's disease and related neurodegenerative conditions, examining how mitochondria (the energy-producing structures in cells) malfunction in dopamine-producing neurons and contribute to disease. His work also extends to gene therapy approaches, including using engineered viruses (AAV vectors) to deliver therapeutic genes like GDNF to the brain for conditions such as Parkinson's disease and alcohol use disorder, as well as gene-editing tools like CRISPR for neurons.
Publication output has been modest but variable over the last decade, with a low base rate in earlier years, a peak of five publications in 2023, and roughly two per year recently.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Delivery of AAV vectors to the superior olivary complex enables efficient adult cochlear transduction via axonal transport
Molecular Therapy · 2025
- Efficient <i>in vivo</i> mammalian neuron editing using peptide-mediated CRISPR enzyme delivery
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Validated assays for the quantification of C9orf72 human pathology
Scientific Reports · 2024
- Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2‐<i>GDNF</i> in a Patient with Parkinson's Disease
Movement Disorders · 2024
- GDNF gene therapy for alcohol use disorder in male non-human primates
Nature Medicine · 2023
- Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy
npj Parkinson s Disease · 2023
- Full-field exposure of larval zebrafish to narrow waveband LED light sources at defined power and energy for optogenetic applications
Journal of Neuroscience Methods · 2023
- GDNF gene therapy for alcohol use disorder in male non-human primates
Zenodo (CERN European Organization for Nuclear Research) · 2023
- GDNF gene therapy for alcohol use disorder in male non-human primates
Zenodo (CERN European Organization for Nuclear Research) · 2023
- Transient exposure of rats to rotenone causes delayed, progressive, parkinsonian motor deficits associated with nigrostriatal degeneration, progressive neuroinflammation and synucleinopathy
Research Square · 2022
- An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function
Journal of Parkinson s Disease · 2021
- α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo
Redox Biology · 2020
- Parkinson's disease
Elsevier eBooks · 2020
- Contributors
Elsevier eBooks · 2020
- Potential Role of Mic60/Mitofilin in Parkinson’s Disease
Frontiers in Neuroscience · 2019
- Neurobiology of Disease×2
- Elsevier eBooks×2
- Zenodo (CERN European Organization for Nuclear Research)×2
- npj Parkinson s Disease×1
- Redox Biology×1
- Sara Sáez-Atiénzar
Medicine · The Ohio State University
- Aswathy Chandran
Medicine · Purdue University West Lafayette
- Allison J. Schaser
Medicine · Purdue University West Lafayette
- Aristide Merola
Medicine · The Ohio State University
- Ariane Park
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile